New Tools for Breast Cancer Risk Assessment
It is important for clinicians to learn about these risk assessment models, understand their limitations and benefits, and determine the best breast cancer risk reduction strategy that can be used for an individual.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Updates in the Management of Biliary Tract Cancers
The advent of novel targeted agents has led to a shift in the treatment paradigm of advanced biliary tract cancers. In recent years, multiple targeted agents were FDA-approved, including tumor-agnostic agents. As such, molecular profiling has become increasingly useful and can potentially help guide treatment decisions.
Category
  • Hepatobiliary Cancers
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Treatment for Pleural and Peritoneal Mesothelioma
Recent phase 3 clinical trial data suggest that surgery and chemotherapy may lead to worse survival outcomes than chemotherapy alone for certain patients with pleural mesothelioma. Additionally, data on other systemic therapy regimens for the treatment of mesothelioma have been recently published.
Category
  • Mesothelioma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer
Clinicians should be aware of all the available systemic therapy regimens as well as updated guideline recommendations on biomarker testing and treatment to ensure that patients with non-metastatic NSCLC receive the most appropriate treatments.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Newer Approaches to Treatment of Bladder Cancer
Recent approvals and clinical trial results continue to enhance treatment options for both BCG-resistant non-muscle invasive bladder cancer and locally advanced/metastatic bladder cancer. Clinicians should be knowledgeable in these recent updates as well as understand how to apply them to their clinical practice.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
Novel agents such as antibody-drug conjugates and immune checkpoint inhibitors have become part of front-line treatment recommendations for advanced stage classic Hodgkin lymphoma over the last several years, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma
The treatment landscape for relapsed/refractory Hodgkin lymphoma has changed significantly in recent years with the incorporation of novel agents such as brentuximab vedotin and the checkpoint inhibitors nivolumab or pembrolizumab. Second-line and subsequent therapy decisions are complex and must take into account multiple factors, such as use of novel agents in the frontline setting and the potential unique toxicities of novel agents.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Updates to Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Best Practices for Oncology Urgent Care
Oncology urgent care is an emerging area of interest requiring many clinical and practical considerations for implementation. Education is needed on the value of offering oncology urgent care and the factors that lead to successful programs.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Updates in the Multidisciplinary Approach for Resectable Gastroesophageal Adenocarcinoma and Peritoneal-Limited Disease
The treatment landscape for gastroesophageal tumors is expanding, including the role of systemic therapy plus surgery. It is essential for healthcare professionals (HCPs) in community and academic settings to be aware of and understand current and emerging treatment options and associated evidence, even that which is limited and may be controversial.
Category
  • Gastric/Esophageal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00

Pages